Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose-reduced Versus Standard Conditioning Followed by Allogeneic Stem Cell Transplantation in Patients With MDS or sAML: A Randomised Phase III Study (RICMAC)

NCT01203228 is registered in ClinicalTrials.gov with European Society for Blood and Marrow Transplantation as lead sponsor.

NCT NCT01203228
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01203228 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose-reduced Versus Standard Conditioning Followed by Allogeneic Stem Cell Transplantation in Patients With MDS or sAML: A Randomised Phase III Study (RICMAC)
Lead sponsor
European Society for Blood and Marrow Transplantation
Phase
Phase 3
Overall status
Terminated
Start date
May 31, 2004
Completion date
February 28, 2015
Enrollment
129 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndromes, secondary acute myeloid leukemia